Feb 21, 2020 17:55 JST
Eisai Receives the President's Award of the Japan Techno-Economics Society at the 8th Technology Management and Innovation Awards
For its Contributions Towards Patients With Liver Disease Through the Eisai-Originated Orally Available Kinase Inhibitor Lenvima
TOKYO, Feb 21, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it received the President's Award at the 8th Technology Management and Innovation Awards held by the Japan Techno-Economics Society (JATES)(1). The award was presented to Eisai for its discovery of the orally available kinase inhibitor LENVIMA (generic name: lenvatinib mesylate) and its contributions towards patients with liver disease.
The Technology Management and Innovation Awards was established in 2012 with the aim of contributing to the development of Japan's economy, social transformation, and global competitiveness by introducing a wide range of outstanding innovations originating in Japan. This year marks the 8th anniversary of the award.
This award symbolizes high evaluation for Eisai's creation of the new treatment LENVIMA in Japan, the expedition of contributions towards patients through its strategic collaboration with Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) to globally co-develop and co-promote LENVIMA, and Eisai's efforts to support patients with liver disease based on its corporate philosophy.
LENVIMA was discovered at Eisai's Tsukuba Research Laboratories. It is an orally administered multiple receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activities of proangiogenic pathway-related RTKs. Eisai obtained the approval of manufacturing and marketing in Japan for LENVIMA indicated for the treatment of unresectable thyroid cancer in March 2015. In March 2018, LENVIMA received its first approval worldwide with an additional indication for unresectable hepatocellular carcinoma (HCC) in Japan. LENVIMA thus became the first systemic therapy to be approved in Japan for front-line treatment of HCC in approximately 10 years. Eisai has also established its own liver disease support site(2) to realize contributions to patients that cannot be achieved with drugs alone. The support site aims to help patients with hepatitis, cirrhosis, and liver cancer to resolve the anxiety they face in treatment and recuperation, as well as to foster a positive mindset towards treatment and an active lifestyle.
Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards healing cancer. In addition to innovation in drug development based on cutting-edge cancer research, Eisai aims to build an oncology ecosystem including prediction and prevention of cancer. Eisai will make continuous efforts to meet the diversified needs of, and increase the benefits provided to patients with cancer, their families, and healthcare professionals.
(1) Institute founded in October 1966 to research technology, management, and economics and facilitate exchange among sectors thereof, to promote industrial activities (Japanese only): http://www.jates.or.jp/
(3) Eisai's Liver Disease Support Site (Japanese only): https://patients.eisai.jp/kanshikkan-support/
About LENVIMA (generic name: lenvatinib mesylate)
LENVIMA, discovered and developed by Eisai, is a multiple receptor tyrosine kinase inhibitor (RTK) that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA also inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to normal cellular function, including fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.
In syngeneic mouse tumor models, LENVIMA decreased the tumor-associated macrophages population and increased the activated cytotoxic T cells population. LENVIMA demonstrated greater antitumor activity in combination with an anti-PD-1 monoclonal antibody compared to either treatment alone.
Currently, LENVIMA has been approved as a treatment for thyroid cancer in over 60 countries including Japan, the United States and in Europe; as a treatment for hepatocellular carcinoma in over 55 countries including Japan, the United States, in Europe, China, and in Asia; as well as in combination with everolimus as a treatment for renal cell carcinoma (second-line) in over 50 countries including the United States, in Europe, and in Asia. Additionally, it was also approved in the combination treatment of LENVIMA plus KEYTRUDA (generic name: pembrolizumab) for advanced endometrial carcinoma in the United States, Australia, and Canada. In Europe, the agent was launched under the brand name Kisplyx for renal cell carcinoma.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit https://www.eisai.com
Public Relations Department,
Eisai Co., Ltd.
Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
More Latest Release >>
Mazda Earns Six IIHS Top Safety Pick+ Awards, the Most Among Automakers Tested for 2020
Apr 08, 2020 11:56 JST
Toyota Motor Corp. and Toyota Group Companies outline efforts towards COVID-19
Apr 07, 2020 15:07 JST
Azabu Insights: Survey Shows 34% increase in Mask Usage in Tokyo
Apr 06, 2020 05:45 JST
Toyota Green Energy Established to Conduct Renewable Energy Power Generation Business
Apr 03, 2020 17:30 JST
Toyota Awarded the 66th Okochi Memorial Production Prize for the Development of an Aluminum Casting Technology
Apr 03, 2020 14:36 JST
Mazda Taking Pre-orders for its 100th Anniversary Special Edition Series in Japan
Apr 03, 2020 12:47 JST
General Motors and Honda to Jointly Develop Next-Generation Honda Electric Vehicles Powered by GM's Ultium Batteries
Apr 03, 2020 09:50 JST
BYD, Toyota Launch BYD TOYOTA EV TECHNOLOGY Joint Venture to Conduct Battery Electric Vehicle R&D
Apr 02, 2020 17:25 JST
Mitsubishi Motors Announces Temporary Production Suspension at a Plant in Japan
Apr 02, 2020 15:10 JST
MHPS: World's Most Efficient Power Plant is Synced to the Grid and Operating at Full Load, Ahead of Schedule
Apr 02, 2020 11:05 JST
Hitachi Announces Establishment of Hitachi Industrial Holdings Americas, Inc. to Strengthen the Industry Business in North America
Apr 01, 2020 17:17 JST
DENSO Invests in Certhon Group, a greenhouse provider based in the Netherlands
Apr 01, 2020 16:52 JST
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China
Apr 01, 2020 16:23 JST
DENSO and Tokyo Tech Establish DENSO Mobility Collaborative Research Cluster
Apr 01, 2020 14:47 JST
NEC Charts Global Growth by Appointing New CEO of Indian Business
Apr 01, 2020 13:17 JST
Outline of Showa Denko CEO Message to Newly-hired Employees
Apr 01, 2020 12:30 JST
DENSO Delivers Technical Support in D-WAVE Project using Quantum Systems to Combat COVID-19
Mar 31, 2020 19:03 JST
MHI Announces Nominations for Outside Directors
Mar 31, 2020 16:13 JST
DENSO Announces Changes in the Areas of Responsibility of Executive Officers
Mar 31, 2020 16:08 JST
MHPS, MHIENG and MGC Selected to Conduct Research on Effective Recycling of CO2 to Produce Methanol
Mar 31, 2020 15:34 JST